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Abstract
Background: A disturbed circadian rhythm seems to be a causal factor in the occurrence of depressive disorders in
patients with Parkinson’s disease (PD). The circadian rhythm can be restored with light. Therefore, Bright Light
Therapy (BLT) might be a new treatment option for depression in PD patients.
Methods/design: In this double-blind controlled trial, 84 subjects with idiopathic PD are randomized to either BLT
or a control light condition. The BLT condition emits white light with an intensity of 10,000 Lux, while the control
device emits dim white light of 200 Lux, which is presumed to be too low to influence the circadian rhythm.
Subjects receive 30 min of home treatment twice daily for three months. Timing of treatment is based on the
individual chronotype. After finishing treatment, subjects enter a follow-up period of six months. The primary
outcome of the study is the severity of depressive symptoms, as measured with the Hamilton Depression Rating
Scale. Secondary outcomes are alternative depression measures, objective and subjective sleep measures, and
salivary melatonin and cortisol concentrations. For exploratory purposes, we also assess the effects on motor
symptoms, global cognitive function, comorbid psychiatric disorders, quality of life and caregiver burden. Data will
be analyzed using a linear mixed models analysis.
Discussion: Performing a placebo-controlled trial on the effects of BLT in PD patients is challenging, as the appearance
of the light may provide clues on the treatment condition. Moreover, fixed treatment times lead to an improved
sleep-wake rhythm, which also influences the circadian system. With our study design, we do not compare BLT to
placebo treatment, i.e. an ineffective control treatment. Rather, we compare structuring of the sleep-wake cycle in
both conditions with additional BLT in the experimental condition, and additional dim light in the control condition.
Participants are not informed about the exact details of the two light devices and the expected therapeutic effect, and
expectancies are rated prior to the start of treatment. Ideally, the design of a future study on BLT should include two
extra treatment arms where BLT and control light are administered at random times.
Trial registration: This trial was registered on ClinicalTrials.gov on May 17th 2012 (ClinicalTrials.gov Identifier:
NCT01604876).




1Department of Psychiatry, VU University Medical Center/GGZ inGeest, A.J.
Ernststraat 887, 1081 HL Amsterdam, The Netherlands
2Department of Anatomy and Neurosciences, VU University Medical Center,
Gustav Mahlerlaan 3004, 1000 MB Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rutten et al. BMC Psychiatry  (2016) 16:355 
DOI 10.1186/s12888-016-1050-z
Background
In patients with Parkinson’s disease (PD), clinically relevant
symptoms of depression occur in up to 35 %, with ap-
proximately 17 % fulfilling criteria for major depressive
disorder (MDD) [1]. Depression has a major impact on
overall functioning: depressed PD patients score lower
on scales assessing activities of daily living, show a
more rapid deterioration of motor and cognitive func-
tioning, and have a higher mortality [2–4]. Depression
is highly correlated with insomnia in PD [5–7], both
contributing to a reduced quality of life in PD patients
and their caregivers [3, 5].
Current treatment options for depression in PD are
limited. Antidepressants can have side effects, such as
orthostatic hypotension, sedation, and anticholinergic ad-
verse effects, and may aggravate motor symptoms [8–10].
Cognitive behavioral therapy might be effective for the
treatment of depression in PD patients, but has not
been extensively studied yet [11]. To date, there are no
evidence-based treatment options for insomnia in PD,
and treatment with hypnotics can have adverse effects
[7]. For patients with cognitive dysfunctions, which are
common in PD [12], psychotherapy is not a always a
feasible treatment option. An alternative treatment for
depressive disorders and insomnia in PD patients is
therefore needed.
Involvement of the circadian system in depression in PD
The circadian rhythm consists of neuroendocrine and
behavioral cycles of approximately 24 h. This rhythm is
generated by the ‘biological clock’, the suprachiasmatic
nucleus (SCN), which is located in the hypothalamus
[13]. The SCN promotes wakefulness during the day and
sleep during the night, providing the body with a pattern
of rest and activity that corresponds to the day-night cycle.
Moreover, the SCN is involved in mood regulation
through the influence on neurotransmitter systems [14].
The circadian system regulates the secretion of several
hormones, including melatonin and cortisol [15]. Under
normal circumstances, the pineal gland starts secreting
melatonin two to three hours prior to bedtime to promote
sleep [15]. When plasma or saliva samples are taken under
dim light conditions, this rise in melatonin levels is re-
ferred to as the dim-light melatonin offset (DLMO) [16].
In the morning, the secretion of melatonin is inhibited by
exposure to light, leading to a decrease in melatonin
concentrations [15]. Cortisol concentrations, on the other
hand, peak in the morning, reflecting the response of the
hypothalamic-pituitary-adrenal axis to awakening [15, 17].
This peak is referred to as the cortisol awakening response
[18]. A more indirect measure of the circadian rhythm is
the chronotype: the propensity of an individual to be
active or asleep during a 24-hour period, with ‘morning’
and ‘evening types’ at the extremes of the spectrum. The
chronotype can be measured with the Morningness –
Eveningness Questionnaire (MEQ) [19]. Previous studies
have shown a significant correlation between the MEQ
score and the DLMO [19, 20].
Since the endogenous rhythm of the SCN is slightly
different from the societal 24-hour day-night cycle, it
has to be entrained by input signals from the environment
called ‘zeitgebers’, such as light, physical activity and food
intake [13, 21]. Disrupting input to the biological clock
can lead to a disturbed circadian rhythm, as reflected in a
shift or change in amplitude of the cortisol and melatonin
secretion patterns. A misalignment of the circadian
rhythm is associated with depressive symptoms and in-
somnia [22–24].
PD patients are prone to desynchronization of the cir-
cadian rhythm, due to dopamine deficiency and conflict-
ing input to the SCN [25]. Indeed, a disturbed circadian
rhythm is observed in this population. Three studies de-
scribed a phase advance of melatonin secretion in PD
subjects [26–28]. Moreover, a decrease in the amplitude
and total amount of melatonin and cortisol secretion has
been observed [29, 30]. In another study, the pattern of
cortisol secretion was also blunted, but total cortisol con-
centrations were increased in PD subjects compared to
healthy controls [31]. These changes in melatonin and
cortisol secretion patterns have also been reported in
non-PD subjects with a depressive disorder or insomnia
[32–34]. Based on these findings, we hypothesize that a
disturbed circadian rhythm is involved in the patho-
physiology of depression and insomnia in PD.
Bright light therapy
Light stimulates melanopsin-containing ganglion cells in
the retina, providing the SCN with a ‘daytime’ signal via
the retinohypothalamic tract [13]. Bright Light Therapy
(BLT) therefore acts as a strong zeitgeber that can restore
circadian rhythmicity. Light exposure in the morning
advances the circadian rhythm and is effective in the
treatment of depressive disorders [35–39], while evening
light delays the rhythm and is thought to be more effective
in the treatment of early awakening insomnia [32]. Since
PD patients have an advanced circadian rhythm [26–28],
evening light might be effective in treating not only in-
somnia, but also depressive symptoms in this population.
In their frequently cited meta-analysis, Golden et al.
(2005) concluded that BLT is effective in the treatment
of depression in non-PD samples [36]. Recent meta-
analyses are more cautious in drawing conclusions on
the efficacy of BLT due to limitations of the performed
studies, e.g. small and heterogeneous study samples, short
treatment duration and lack of a proper placebo condition
[35, 37, 38]. The same issue was raised in a Cochrane re-
view on the effects of BLT for treating insomnia in adults
aged 60 years and older [40]. However, since treatment
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effects of pharmacotherapy alone for these disorders are
limited, and BLT is a low-cost treatment with a relatively
high safety and tolerability [41], it is a treatment option
that deserves further research.
In PD, the effects of BLT have been evaluated in two
pilot studies [42, 43] and one retrospective, open label
study [44]. These studies demonstrated positive effects
on depressive symptoms, sleep and motor symptoms.
However, depression was not the primary outcome
measure in all studies, and all studies had methodo-
logical limitations. Therefore, further research on the ef-
ficacy of BLT in the treatment of PD patients with a
depressive disorder is warranted.
Methods
This study aims to investigate whether BLT is more ef-
fective in reducing depressive symptoms in patients with
PD and a depressive disorder, than a control light device.
For secondary research purposes, we assess the effects of
BLT on insomnia and circadian rhythmicity.
Study design and procedures
The design of this study is a double-blind randomized
controlled clinical trial. An overview of all study proce-
dures is given in Table 1.
After (self-)referral, subjects are sent an information
package about the study. If still interested in participation
after reading the additional information, prospective par-
ticipants are screened by telephone by the first assessor
(SR, psychiatry resident). When eligible, subjects are in-
vited for an appointment with the first assessor. During
this visit, subjects can ask any remaining questions. After
providing written informed consent, subjects are random-
ized to the experimental or control condition by a re-
search coordinator (CV), and baseline clinical assessments
are performed. At the end of the visit, subjects are asked
Table 1 Overview of study procedures
HDRS Hamilton Depression Rating Scale, GDS-30 30-item Geriatric Depression Scale, SCOPA-SLEEP Scales for Outcomes in Parkinson’s Disease-Sleep, CSD Consensus
Sleep Diary, MEQ Morningness-Eveningness Questionnaire, SCID-I Structured Clinical Interview for DSM-IV Axis I Disorders, UPDRS Unified Parkinson’s Disease Rating
Scale, MMSE Mini Mental State Examination, WHO-QOL-BREF World Health Organization Quality of Life assessment, abbreviated version; ZBI Zarit Burden Interview,
CEQ Credibility/Expectancy Questionnaire
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to perform actigraphy, keep a sleep diary and wear a light
sensor at home for the upcoming seven days. After this
week, all baseline assessments are completed and a BLT
or control device is installed at the subject’s home by the
study coordinator or a trained research assistant. After a
demonstration of the device, the three-month treatment
phase starts. Clinical assessments are repeated halfway
(T1) and at the end of treatment (T2). After completing
treatment, subjects enter a six-month follow-up phase.
Subsequent interventions are allowed within the follow-
up phase, since we consider it unethical to withhold treat-
ment from patients with remaining depressive symptoms.
Follow-up assessments take place one (T3), three (T4)
and six months (T5) after completing treatment. Prior to
each follow-up assessment, subjects receive a package
containing questionnaires, a sleep diary, actigraphy watch,
light sensor and cotton dental rolls for saliva sampling, to
perform these measures at home in the week prior to the
assessment visit.
Randomization and blinding
To maintain blinding of the assessors, the research co-
ordinator (CV) performs block randomization. Blocks
are generated per season to rule out seasonal influences
on the treatment effect. Both subjects and assessors are
blinded for the treatment condition. To prevent unblinding,
subjects are asked not to share any details of their treat-
ment with their assessor. When patients do reveal their
condition, the assessor is immediately replaced by the
blinded project’s principle investigator (OvdH, psychiatrist).
Participants
Participants for this study are recruited throughout the
Netherlands by various strategies, including referral by a
neurologist, psychiatrist or other medical professional, re-
cruitment through media of various associations involved
with PD, and advertisement in a Dutch national newspaper.
Patients are eligible for inclusion when they are diag-
nosed with idiopathic PD by a neurologist. In addition,
they are required to meet criteria of a major depressive
disorder as classified by the DSM-IV [45]. Patients with a
bipolar disorder are excluded due to the risk of inducing
(hypo)mania with BLT [38]. We also exclude subjects with
a current psychosis, due to the potential influence on our
assessments and the risk of noncompliance. Finally, we ex-
clude patients with a (relative) contraindication for BLT,
such as a disorder associated with photosensitization reac-
tions to light, e.g. porphyria, macular degeneration, retinal
dystrophy, or lupus erythematosus, or when they have
used pharmacological agents with a photosensitizing effect
within the past four weeks [20]. Because changes in the
use of antiparkinsonian or psychiatric medication might
influence assessments, participants have to be on a
stable dose of medication for at least four weeks before
inclusion. Moreover, subjects and their physicians are
asked not to change the medication regime during the
treatment phase of the trial, unless this is deemed med-
ically necessary.
Intervention
The experimental condition consists of BLT with a Brazil®
Lightbox (Lumie, Cambridge, United Kingdom). This BLT
device emits white, broad spectrum light. During treatment
sessions, subjects are instructed to take place in front of
the device at a distance of 30 cm, at which the intensity of
the light is 10,000 Lux. To create a credible control condi-
tion, neutral density filters (Lee Filters, type 209.03ND,
Hampshire, United Kingdom) are installed in the light
device, so that the experimental and control device have
an identical appearance when switched off. These filters
reduce transmission uniformly, giving the light a dim
white appearance. Subjects are instructed to position
themselves at a distance of 40 cm from the control de-
vice, at which the light intensity is approximately 200
Lux. At this light intensity, which is lower than in a
dimly lit room, no substantial effect on circadian rhyth-
micity is expected [46].
Subjects in both conditions follow the treatment at
home for a period of three months. Subjects use the de-
vice both in the morning and the evening. Treatment
duration per session is 30 min, which is sufficient to en-
train the SCN at an intensity of 10,000 Lux [20]. Timing
of the morning treatment session is based on the score
on the MEQ [19, 41].
Since evening BLT should be administered at least
90 min prior to bedtime [20], the evening session takes
place 9. Five hours prior to the morning BLT, in order to
allow eight hours of nighttime sleep. To increase user
convenience and compliance, the device is attached to a
timer, so that the device switches on automatically at the
times set for treatment.
Outcomes
Primary outcome measure
The primary outcome measure of this study is the change
in depressive symptoms as regards to baseline, as mea-
sured with the 17-item version of the Hamilton De-
pression Rating Scale (HDRS) [47], from baseline (T0)
to the end of treatment (T2).
Secondary outcome measures
Our secondary outcome measures are (1) alternative de-
pression measures, (2) subjective and objective quality of
sleep, and (3) circadian rhythmicity. Since we are mainly
interested in the direct and long-term treatment effects,
all outcome measures described below concern the differ-
ence between the treatment groups in the change in out-
come measures as regards to the baseline value between i)
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baseline and the end of treatment (T0 to T2) and ii)
baseline and the end of follow-up (T0 to T5).
1. Additional depression measures:
The change in HDRS-score between T0 and T5 is
considered as a secondary outcome measure. As an
alternative measure for depression, we use the
Geriatric Depression Scale (GDS-30) [48], a self-
report instrument. The GDS-30 does not contain
items regarding somatic symptoms of depression, and
might therefore have a higher diagnostic specificity in
PD [48]. As a third depression measure, we assess the
proportion of subjects in each treatment group that
achieves complete remission at T2 and T5, i.e.
fulfilling DSM-IV criteria of a ‘depressive disorder
in full remission’, as determined with the Structured
Clinical Interview for DSM-IV Axis I disorders
(SCID-I) [49].
2. Sleep:
a. Subjective experience of sleep is measured with the
Scales for Outcomes in Parkinson’s Disease-Sleep
(SCOPA-SLEEP) [50], a validated self-report
instrument that contains two subscales: one rating
nighttime sleep disturbances and one on excessive
daytime sleepiness. Both subscale scores are used
as a secondary outcome measure.
b. Sleep patterns are objectified by actigraphy,
which is considered to be a valid alternative for
polysomnography in the quantitative evaluation
of sleep in PD patients [51]. Subjects are asked to
wear an actigraphy device (GENEActiv Sleep;
GENEActiv, Huntingdon, United Kingdom) on
their non-dominant wrist continuously for seven
consecutive days. Sleep parameters are calculated in
two steps. First, accelerometry data is preprocessed
with GENEActive PC software version 2.2, using
reports of time of attempted sleep and time of final
awakening from the Consensus Sleep Diary (CSD)
[52]. Second, the raw GENEActive accelerometry
data are converted into Actiwatch counts, as
described by Te Lindert et al. (2013), to calculate
sleep parameters. The sleep parameters of main
interest are total sleep time and sleep fragmentation,
i.e. the number of wake bouts per night.
3. Circadian rhythmicity:
In this study, we use salivary concentrations of
melatonin and cortisol as markers for the circadian
rhythm. At each time point in the study, subjects
are instructed to collect saliva at home during a
single day, using cotton dental rolls (Salivette®,
Sarstedt, Numbrech, Germany). The first saliva
sample is taken immediately after waking up,
followed by three more samples at an interval of
30 min. In the evening, subjects start hourly
collection of samples four hours prior to intended
bedtime. Samples are preserved in the refrigerator
by the patient, and collected by the researchers one
or two days later. They are centrifuged and stored
at −80 °C until all samples of one subject that are
collected throughout the study can be analyzed
simultaneously. The cortisol concentration in the
saliva samples is determined by on-line solid-phase
extraction liquid chromatography tandem mass
spectrometry (XLS-MS/MS), which is preferred over
immunoassays to prevent cross-reactivity with other
corticosteroids [53]. We will calculate the area under
the curve with respect to the ground (AUCG) and
the area under the curve with respect to the index
of salivary cortisol change over time (AUCI), as de-
scribed by Pruessner et al. (2003) [54]. The AUCG is
an estimate of the total cortisol secretion throughout
the day, whereas the AUCI is a measure of the corti-
sol awakening response. The AUCG and AUCI of
the salivary cortisol concentrations of the morning
samples are considered as a secondary outcome
measure. We will also report the cortisol concen-
tration in the first saliva sample taken as a measure
of the endpoint of pre-awakening increase in corti-
sol [17]. The melatonin concentrations are assessed
in the evening saliva samples using liquid chroma-
tography tandem mass spectrometry (LS-MS/MS).
We will calculate the DLMO with the ‘hockey-stick
method’, as described by Danilenko et al. (2013)
[55].
Assessments for exploratory purposes
For exploratory purposes, we assess the difference be-
tween the treatment groups in the absolute change in
the following outcome measure from T0 to T2 and T0
to T5.
1. Subjective quality of sleep, rated in the CSD on a
scale ranging from 0 (very poor) to 4 (very good).
2. Sleep efficiency as objectified with actigraphy. Sleep
efficiency is defined as the percentage of time the
subject spent asleep between onset of sleep and
getting up in the morning.
3. Evening cortisol secretion, calculated as both the
AUCG and AUCI.
4. Global cognitive function, assessed with the Mini
Mental State Examination (MMSE) [56].
5. Presence of comorbid psychiatric disorders, as
determined with the SCID-I.
6. Severity of motor symptoms, using section III of the
Unified Parkinson’s Disease Rating Scale (UPDRS)
[57]. The UPDRS-III is rated by the first assessor, who
is trained by a movement disorder specialist (HB).
7. The chronotype, as determined with the MEQ.
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8. Quality of life, as measured with the abbreviated
version of the World Health Organization Quality of
Life assessment (WHOQOL-BREF) [58].
9. Caregiver burden, as reported by the caregiver on
the Zarit Burden Interview (ZBI) [59].
Covariates
In order to control for factors that might influence the
association between treatment and the outcome measures,
we collect the following additional data:
1. Medication use:
Current medication use is reviewed at each
assessment. Since dopaminergic agents can have a
positive influence on mood in PD patients with
depressive symptoms [60], we will control for the
total dose of dopaminomimetics, which is converted
to a levodopa equivalent daily dose using the
conversion rate described by Olde Dubbelink et al.
(2013) [61]. Moreover, we will correct for the
initiation or change in dosage of antidepressants or
sleep medication.
2. Exposure to environmental light:
We collect data on the exposure to environmental
light using a light sensor (Actiwatch Light®,
Cambridge Neurotechnology Ltd., Cambridge UK).
Subjects are asked to continuously wear the sensor
on the outer layer of their clothing for seven
consecutive days. Raw data on light exposure is
preprocessed with Actiwatch Activity & Sleep
Analysis 5 software, after which total amount of
light exposure during the day is calculated using
custom-made in-house software.
3. Expectancy
In a previous study on BLT, a positive correlation
between expectations and treatment response was
found [62]. In this study, we assess the expectancies
of our subjects with the Credibility/Expectancy
Questionnaire (CEQ) [63], after installation of the
device at home.
4. Compliance:
Compliance with treatment is assessed with an
occupancy data logger (HOBO® occupancy/light
logger) that is attached to the device. The logger
detects the time and duration of presence of the
participant in front of the device. Treatment session
compliance is defined as exposure to the device for
at least 70 % of the prescribed duration, i.e. 21 out
of 30 min, within the set time frame. Total
compliance is calculated as the proportion of
sessions that a subject is compliant with therapy.
We assess the effects of total compliance on the
intervention effect, as well as compliance with
morning and evening therapy separately.
Side effects and treatment satisfaction
Prior to the start of the trial, we made an overview of
potential adverse effects that subjects might experience
during treatment, based on previous reports [41, 64].
One week after the start of treatment, subjects are con-
tacted by telephone by the research assistant to inquire
about these side effects. At assessment visit T1, patients
are also screened for side effects. We will report the dif-
ference in prevalence of reported side effects between
both groups.
After completing the treatment phase, all patients are
asked to rate their appreciation of timing and duration
of therapy sessions on a visual analogue scale (VAS).
Moreover, they indicate on a VAS the extent to which
they would like to continue treatment after the end of
the trial. We will report average VAS scores as an indica-
tor of treatment satisfaction per group.
Statistical analysis
Sample size calculation
Prior to the start of the study, we calculated the neces-
sary sample size for a sufficient power at the end of
treatment (T2) in a mixed models analysis. We aimed to
have sufficient sensitivity for a minimal standardized ef-
fect size of Cohen’s d = 0.6, with an estimated standard
deviation of 1.0 and intra-subject correlation of assess-
ments of ρ = 0.6. For a statistical power of 80 % and a
two-tailed significance level of p < 0.05, 35 subjects per
treatment group were required. To correct for a max-
imum drop-out of 20 %, we would need 7 additional
subjects per group, resulting in a total sample size of 84
subjects.
Efficacy analysis
Analyses will be performed on the Modified-Intent-To-
Treat population, which consists of all subjects random-
ized in the trial who received at least one week of light
treatment and provided at least one post-baseline assess-
ment of the HDRS. As a sensitivity analysis, we will com-
pare the baseline characteristics to the Intent-to-Treat
population, i.e. all subjects who were randomized in the
trial. To assess the effect of treatment duration, we will
also assess the effects in the Per Protocol-population, i.e.
all subjects who completed the three months treatment
duration.
Demographics and clinical characteristics of both the
BLT and control group at baseline will be presented with
percentages or mean scores with standard deviations.
Correlations between continuous variables at baseline will
be calculated using Pearson’s correlation coefficients.
The effect of the intervention on the change from T0
to T2, and from T0 to T5, in outcome measures will be
assessed using a linear mixed-effects model analysis
with assessment visit as the lowest level, and patient as
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highest level. Time of assessment will be handled as a
categorical variable. The effect of the intervention on
the outcome measures over time will be modeled by an
intervention by time interaction with two degrees of
freedom. In all analyses, we will correct for baseline
values of the outcome variable. In addition, we will as-
sess whether adding the covariates to the regression
model leads to a significant change of the regression
coefficient of the condition effect of ≥10 %.
No imputation of missing values will be performed,
since linear mixed models handle missing data by pla-
cing the data in long format, where the available data of
each measurement is nested within persons.
Discussion
Performing a placebo-controlled trial on the effects of
BLT is challenging, since the appearance of the device or
the characteristics of the emitted light can provide the
subject with clues about the treatment condition. This
can influence the subject’s expectancies of the treatment,
which has been shown to impact on the outcomes of a
study on BLT the past [62]. Deactivated negative ion-
izers, dim red light and light boxes with full-band filters
were used as control light conditions for BLT in previous
studies [37, 65]. In this trial, we also use a light device
with full-band filter. However, the reduced intensity of
the light could point out that the subjects in the control
condition were not receiving BLT. Therefore, subjects’
expectancies are rated prior to the start of treatment,
and participants are not informed about the exact details
of the two light devices and their expected therapeutic
effect. Although this might raise ethical questions, it is a
valid way to guarantee subject blinding when studying a
treatment that lacks a credible placebo condition. There-
fore, this study did receive approval of the ethics com-
mittee. Moreover, the subjects in the control condition
do receive some form of treatment. All subjects in our
study are required to use the light device at fixed times
in the morning and the evening, imposing a fixed sleep-
wake structure on all participants. According to the ‘social
zeitgeber’ hypothesis of Ehlers et al. (1988), a disruption of
social rhythms can induce a depressive episode through
disturbance of the circadian rhythm [66]. Restoring the
circadian rhythm by re-establishing daily routines, includ-
ing time of awakening and going to bed, might therefore
have a positive influence on mood [66]. Since all partici-
pating subjects in our study achieve a more regular sleep-
wake cycle, we feel that subjects in the control condition
are not completely deprived of treatment. Moreover, a
report by Zeiter et al. (2000) suggests that dim light of
approximately 100 lux also has the ability to cause a
shift in circadian rhythm [67]. Although the healthy
volunteers participating in this study were exposed to the
light for 6.5 h [67], we cannot rule out the possibility that
30 min of exposure to 200 lux of light will influence the
circadian system of PD patients.
With our study design, we do not compare BLT to
‘pure’ placebo treatment, i.e. an ineffective control treat-
ment. Rather, we compare structuring of the sleep-wake
cycle through set treatment times in both conditions,
with additional BLT in the experimental condition, and
additional dim light in the control condition. In order to
be able to assess the effects of BLT only, a future study
on the effects of BLT on depression in PD would have
two additional treatment arms, where BLT and control
light are administered at random times. Moreover, more
research is needed on the timing (morning or evening)
and duration of BLT, as well as the influence of light in-
tensity. However, we hypothesize that with the design of
this study, we will still find a greater improvement on
depression, insomnia and biomarkers of circadian rhyth-
micity in the subjects in our experimental condition as
compared to our control subjects, due to the addition of
BLT to the imposed sleep-wake structure.
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